137 related articles for article (PubMed ID: 37684129)
1. Convergent insights into intratumor heterogeneity.
Manini C; Laruelle A; Rocha A; López JI
Trends Cancer; 2024 Jan; 10(1):12-14. PubMed ID: 37684129
[TBL] [Abstract][Full Text] [Related]
2. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.
Manini C; López-Fernández E; Lawrie CH; Laruelle A; Angulo JC; López JI
Curr Urol Rep; 2022 Jun; 23(6):93-97. PubMed ID: 35416538
[TBL] [Abstract][Full Text] [Related]
3. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Gerlinger M; Rowan AJ; Horswell S; Math M; Larkin J; Endesfelder D; Gronroos E; Martinez P; Matthews N; Stewart A; Tarpey P; Varela I; Phillimore B; Begum S; McDonald NQ; Butler A; Jones D; Raine K; Latimer C; Santos CR; Nohadani M; Eklund AC; Spencer-Dene B; Clark G; Pickering L; Stamp G; Gore M; Szallasi Z; Downward J; Futreal PA; Swanton C
N Engl J Med; 2012 Mar; 366(10):883-892. PubMed ID: 22397650
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.
Li Y; Lih TM; Dhanasekaran SM; Mannan R; Chen L; Cieslik M; Wu Y; Lu RJ; Clark DJ; Kołodziejczak I; Hong R; Chen S; Zhao Y; Chugh S; Caravan W; Naser Al Deen N; Hosseini N; Newton CJ; Krug K; Xu Y; Cho KC; Hu Y; Zhang Y; Kumar-Sinha C; Ma W; Calinawan A; Wyczalkowski MA; Wendl MC; Wang Y; Guo S; Zhang C; Le A; Dagar A; Hopkins A; Cho H; Leprevost FDV; Jing X; Teo GC; Liu W; Reimers MA; Pachynski R; Lazar AJ; Chinnaiyan AM; Van Tine BA; Zhang B; Rodland KD; Getz G; Mani DR; Wang P; Chen F; Hostetter G; Thiagarajan M; Linehan WM; Fenyö D; Jewell SD; Omenn GS; Mehra R; Wiznerowicz M; Robles AI; Mesri M; Hiltke T; An E; Rodriguez H; Chan DW; Ricketts CJ; Nesvizhskii AI; Zhang H; Ding L;
Cancer Cell; 2023 Jan; 41(1):139-163.e17. PubMed ID: 36563681
[TBL] [Abstract][Full Text] [Related]
5. Precision sampling fuels precision oncology: an evolutionary perspective.
Manini C; López-Fernández E; López JI
Trends Cancer; 2021 Nov; 7(11):978-981. PubMed ID: 34493466
[TBL] [Abstract][Full Text] [Related]
6. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
Gerlinger M; Horswell S; Larkin J; Rowan AJ; Salm MP; Varela I; Fisher R; McGranahan N; Matthews N; Santos CR; Martinez P; Phillimore B; Begum S; Rabinowitz A; Spencer-Dene B; Gulati S; Bates PA; Stamp G; Pickering L; Gore M; Nicol DL; Hazell S; Futreal PA; Stewart A; Swanton C
Nat Genet; 2014 Mar; 46(3):225-233. PubMed ID: 24487277
[TBL] [Abstract][Full Text] [Related]
7. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
Hsieh JJ; Manley BJ; Khan N; Gao J; Carlo MI; Cheng EH
Semin Cell Dev Biol; 2017 Apr; 64():98-106. PubMed ID: 27615548
[TBL] [Abstract][Full Text] [Related]
8. Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Tannock IF
Eur Urol; 2014 Apr; 65(4):846-7. PubMed ID: 24559903
[No Abstract] [Full Text] [Related]
9. Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.
Hoefflin R; Lahrmann B; Warsow G; Hübschmann D; Spath C; Walter B; Chen X; Hofer L; Macher-Goeppinger S; Tolstov Y; Korzeniewski N; Duensing A; Grüllich C; Jäger D; Perner S; Schönberg G; Nyarangi-Dix J; Isaac S; Hatiboglu G; Teber D; Hadaschik B; Pahernik S; Roth W; Eils R; Schlesner M; Sültmann H; Hohenfellner M; Grabe N; Duensing S
Nat Commun; 2016 Jun; 7():ncomms11845. PubMed ID: 27291893
[TBL] [Abstract][Full Text] [Related]
10. Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist.
López JI
APMIS; 2016 Mar; 124(3):153-9. PubMed ID: 26865355
[TBL] [Abstract][Full Text] [Related]
11. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
[TBL] [Abstract][Full Text] [Related]
12. Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.
López JI; Angulo JC
Curr Urol Rep; 2018 Jan; 19(1):3. PubMed ID: 29374850
[TBL] [Abstract][Full Text] [Related]
13. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.
Gerlinger M; Quezada SA; Peggs KS; Furness AJ; Fisher R; Marafioti T; Shende VH; McGranahan N; Rowan AJ; Hazell S; Hamm D; Robins HS; Pickering L; Gore M; Nicol DL; Larkin J; Swanton C
J Pathol; 2013 Dec; 231(4):424-32. PubMed ID: 24122851
[TBL] [Abstract][Full Text] [Related]
14. Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity.
Miheecheva N; Postovalova E; Lyu Y; Ramachandran A; Bagaev A; Svekolkin V; Galkin I; Zyrin V; Maximov V; Lozinsky Y; Isaev S; Ovcharov P; Shamsutdinova D; Cheng EH; Nomie K; Brown JH; Tsiper M; Ataullakhanov R; Fowler N; Hsieh JJ
Cell Rep; 2022 Aug; 40(7):111180. PubMed ID: 35977503
[TBL] [Abstract][Full Text] [Related]
15. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
Cai Q; Christie A; Rajaram S; Zhou Q; Araj E; Chintalapati S; Cadeddu J; Margulis V; Pedrosa I; Rakheja D; McKay RM; Brugarolas J; Kapur P
EBioMedicine; 2020 Jan; 51():102526. PubMed ID: 31859241
[TBL] [Abstract][Full Text] [Related]
16. Snail heterogeneity in clear cell renal cell carcinoma.
Zaldumbide L; Erramuzpe A; Guarch R; Pulido R; Cortés JM; López JI
BMC Cancer; 2016 Mar; 16():194. PubMed ID: 26951092
[TBL] [Abstract][Full Text] [Related]
17. Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients.
Saout JR; Lecuyer G; Léonard S; Evrard B; Kammerer-Jacquet SF; Noël L; Khene ZE; Mathieu R; Brunot A; Rolland AD; Bensalah K; Rioux-Leclercq N; Lardenois A; Chalmel F
Eur Urol; 2023 May; 83(5):441-451. PubMed ID: 36801089
[TBL] [Abstract][Full Text] [Related]
18. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas.
Zhu B; Poeta ML; Costantini M; Zhang T; Shi J; Sentinelli S; Zhao W; Pompeo V; Cardelli M; Alexandrov BS; Otlu B; Hua X; Jones K; Brodie S; Dabrowska ME; Toro JR; Yeager M; Wang M; Hicks B; Alexandrov LB; Brown KM; Wedge DC; Chanock S; Fazio VM; Gallucci M; Landi MT
Nat Commun; 2020 Jun; 11(1):3096. PubMed ID: 32555180
[TBL] [Abstract][Full Text] [Related]
19. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma.
Guarch R; Lawrie CH; Larrinaga G; Angulo JC; Pulido R; López JI
Ann Diagn Pathol; 2018 Jun; 34():27-30. PubMed ID: 29661723
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
